Compliance issues at Integra and Hologic facilities have caught the US Food and Drug Administration’s attention, with the agency publishing lengthy warning letters to both companies on 14 January.
The 18 December Hologic letter discusses the FDA’s findings during a late-summer 2024 inspection of the company’s Marlborough, Mass., headquarters. The facility makes